[A reduction study of seroconversion of HBsAg in chronic hepatitis B patients with HBeAg positive by combination treatment with interferon and lamivudine].
Yu
Shu-li
SL
Department of Infectious Diseases, Hospital of Infectious of Jinan, Jinan, China. yushuli999@126.com
Qin
Lan-ying
LY
Wang
Can
C
Yu
Li-jun
LJ
Guo
Chao-ying
CY
Wang
Yao-zong
YZ
D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004279:DNA, Viral / Q000097:blood; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D016898:Interferon-alpha; D019259:Lamivudine